CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
AI-guided surgeryprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05735171
NCT05735171N/ACompleted

Tailored Supramarginal Resection in Glioblastoma Guided by Artificial Intelligence-based Recurrence Probability Maps. A Non-randomized Pilot Study

Hospital del Rio Hortega·interventional·Posted Feb 21, 2023·Updated Dec 24, 2025

In Brief

A clinical study evaluating AI-guided surgery for Glioblastoma. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Glioblastomas are the most common and poorly prognostic primary brain neoplasms. Despite advances in surgical techniques and chemotherapy, the median survival time for these patients remains less than 15 months. This highlights the need for more effective treatments and improved prognostic tools. The globally accepted surgical strategy currently consists of achieving the maximum safe resection of the enhancing tumor volume. However, the non-enhancing peritumoral region contains viable cells that cause the inevitable recurrence that these patients face. Clinicians currently lack an imaging tool or modality to differentiate neoplastic infiltration in the peritumoral region from vasogenic edema. In addition, it is not always feasible to include all the T2-FLAIR signal alterations surrounding the enhancing tumor in the surgical planning due to the proximity of eloquent areas and the higher risk of postoperative deficits. However, the investigators have developed a model to predict regions of recurrence based on machine learning and MRI radiomic features that have been trained and evaluated in a multi-institutional cohort. The investigators aim to analyze whether an adjusted supramarginal resection guided by these new recurrence probability maps improves survival in selected patients with glioblastoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesSpain

Timeline

N/ACompletedFinished
2023202420252026
First PostedFeb 21, 2023
Enrollment StartNov 1, 2022
Primary CompletionMay 30, 2025
Study CompletionDec 1, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 3.4 years ago

Interventions

AI-guided surgeryprocedure

Neuronavigated targeted biopsy sampling. Supramarginal resection including high-risk areas of recurrence defined by a radiomics-based model.